Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antidepressant |
| gptkbp:activeIngredient |
gptkb:agomelatine
|
| gptkbp:approvalYear |
2009
|
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
N06AX22
|
| gptkbp:brand |
gptkb:Melitor
gptkb:Thymanax gptkb:Valdoxan |
| gptkbp:CASNumber |
138112-76-2
|
| gptkbp:chemicalFormula |
C15H17NO2
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:contraindication |
hepatic impairment
|
| gptkbp:developedBy |
gptkb:Servier_Laboratories
|
| https://www.w3.org/2000/01/rdf-schema#label |
Valdoxan
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
5-HT2C antagonist
melatonergic agonist |
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness headache liver enzyme increase |
| gptkbp:usedFor |
gptkb:major_depressive_disorder
|
| gptkbp:bfsParent |
gptkb:D08402
gptkb:阿戈美拉汀 |
| gptkbp:bfsLayer |
6
|